Fig. 4

DEPTH2 ITH correlating negatively with antitumor immune response and immunotherapy response. Spearman correlations between DEPTH2 scores and the enrichment levels of antitumor immune signatures (CD8+ T cells, NK cells, immune cytolytic activity, and interferon (IFN) response) (A), ratios of immune-stimulatory/immune-inhibitory signatures (CD8+/CD4+ regulatory T cells) (B), and PD-L1 expression levels (C) in pan-cancer and individual cancer types. D High-DEPTH2-score (> median) tumors show a lower response rate to immune checkpoint inhibitors (ICIs) than the low-DEPTH2-score (< median) tumors in four cancer cohorts receiving anti-PD-1/PD-L1/CTLA-4 immunotherapies, and DEPTH2 scores are significantly lower in the tumors responsive to ICIs than in the tumors not responsive to ICIs in the Allen cohort